Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Sarolta Nahajevszky"'
Autor:
Sarolta Nahajevszky, Hajnalka Andrikovics, Arpad Batai, Emma Adam, Andras Bors, Judit Csomor, Laszlo Gopcsa, Magdalena Koszarska, Andras Kozma, Nora Lovas, Sandor Lueff, Zoltan Matrai, Nora Meggyesi, Janos Sinko, Andrea Sipos, Andrea Varkonyi, Sandor Fekete, Attila Tordai, Tamas Masszi
Publikováno v:
Haematologica, Vol 96, Iss 11 (2011)
Background Prognostic risk stratification according to acquired or inherited genetic alterations has received increasing attention in acute myeloid leukemia in recent years. A germline Janus kinase 2 haplotype designated as the 46/1 haplotype has bee
Externí odkaz:
https://doaj.org/article/ac88012fc4f3488ab632138d40c784fc
Autor:
Andrea Sipos, Sandor Lueff, Árpád Bátai, Anikó Barta, András Bors, András Kozma, Péter Reményi, Emma Ádám, Attila Tordai, Hajnalka Andrikovics, Gabriella Halm, György Ujj, Sarolta Nahajevszky, Nóra Meggyesi, Sandor Fekete, Tamas Masszi
Publikováno v:
Acta Haematologica. 127:34-42
Background: Additional chromosome abnormalities (ACAs), mutations of the BCR-ABL tyrosine kinase domain (TKD) and BCR-ABL splice variants may cause resistance to first- and second-generation tyrosine kinase inhibitors (TKIs) in chronic myelogenous le
Autor:
László Homolya, Attila Kiss, Béla Telek, János Kappelmayer, L. Rejto, Éva Karászi, Sarolta Nahajevszky, Balázs Sarkadi, Gergely Szakács, Katalin Jakab, Zsolt Holló
Publikováno v:
British Journal of Haematology. 112:308-314
In this study, we evaluated the suitability of the calcein assay as a routine clinical laboratory method for the identification of multidrug-resistant phenotype in acute leukaemia. This study presents the results of the calcein tests obtained in two
Autor:
Janos Sinko, Attila Tordai, Magdalena Koszarska, Andrea Sipos, Árpád Bátai, Tamás Masszi, Sarolta Nahajevszky, Nóra Meggyesi, László Gopcsa, Judit Csomor, Andrea Várkonyi, Zoltán Mátrai, Sándor Fekete, András Bors, Sandor Lueff, Nóra Lovas, Emma Ádám, Hajnalka Andrikovics, András Kozma
Publikováno v:
Haematologica. 96(11)
Background Prognostic risk stratification according to acquired or inherited genetic alterations has received increasing attention in acute myeloid leukemia in recent years. A germline Janus kinase 2 haplotype designated as the 46/1 haplotype has bee
Autor:
Attila Tordai, Miklos Egyed, Magdalena Koszarska, Z. Matrai, N. Lovas, Nóra Meggyesi, Andrea Sipos, Gábor Mikala, Sandor Lueff, Gabriella Halm, A. Kozma, S. Fekete, E. Adam, Tamás Masszi, Hajnalka Andrikovics, R Rasonyi, Judit Várkonyi, A. Bors, Sarolta Nahajevszky, Judit Csomor
Publikováno v:
Leukemia. 24(10)
Somatic gain-of-function mutation of the Janus kinase (JAK2) gene (NM_004972.2: c.1849G>T transversion resulting in V617F) has been identified in BCR–ABL-negative chronic myeloproliferative neoplasms (MPNs) (in >95% of polycythaemia vera (PV), and
Autor:
Sarolta Nahajevszky, Anna Poros, Attila Tordai, András Kozma, Béla Kajtár, Anikó Szilvási, Hajnalka Andrikovics, Anikó Barta, András Bors, Emma Ádám
Publikováno v:
Hematological oncology. 25(3)
During the formation of the Philadelphia (Ph) chromosome, in the majority of chronic myelogenous leukemia (CML) patients, the chromosome 22 breakpoint is located in the major breakpoint cluster region of the BCR gene (M-bcr). Minor and micro breakpoi
Autor:
Zoltán Mátrai, Andrea Sipos, Attila Tordai, Sandor Lueff, Gabriella Halm, Anikó Szilvási, Tamas Masszi, Viktória Király, Gabor Mikala, Zoltán Csukly, Sarolta Nahajevszky, Júlia Tamáska, Nóra Meggyesi, Hajnalka Andrikovics, Nóra Lovas
Publikováno v:
Orvosi hetilap. 148(5)
The Val617Phe point mutation of Janus kinase 2 gene is believed to participate in the pathogenesis of myeloproliferative syndrome characterised by the clonal alteration of hematopoetic stem cells. According to current results, the frequency of Val617
Autor:
Carine Robert, Béla Papp, Laurent Delva, Tamas Masszi, Nicole Balitrand, Christine Chomienne, Sarolta Nahajevszky
Publikováno v:
Cancer research. 66(12)
Hypereosinophilic syndrome (HES) has recently been recognized as a clonal leukemic lesion, which is due to a specific oncogenic event that generates hyperactive platelet-derived growth factor receptor-α–derived tyrosine kinase fusion proteins. In
Autor:
Sarolta, Nahajevszky, Balázs, Kapás, Emma, Adám, Nóra, Lovas, Gabriella, Halm, László, Gopcsa, Júlia, Tamáska, Anna, Poros
Publikováno v:
Orvosi hetilap. 145(4)
Treatment outcome in patients with acute myeloid leukemia are determined by prognostic factors.Between January 1996 and December 2001 160 patients were treated with newly diagnosed acute myeloid leukemia. Treatment results were analysed according to
Autor:
E. Adam, P. Reményi, Z. Csukly, N. Lovas, A. Batai, Gabriella Halm, T. Masszi, B. Kapás, Nóra Meggyesi, Attila Tordai, Sandor Lueff, A. Kozma, H. Andrikovics, Sarolta Nahajevszky
Publikováno v:
Blood Reviews. 21:S78-S79